Kiessling Anke, Sperl Bianca, Hollis Angela, Eick Dirk, Berg Thorsten
Department of Molecular Biology, Max Planck Institute of Biochemistry, Martinsried, Germany.
Chem Biol. 2006 Jul;13(7):745-51. doi: 10.1016/j.chembiol.2006.05.011.
bZip and bHLHZip protein family members comprise a large fraction of eukaryotic transcription factors and need to bind DNA in order to exert most of their fundamental biological roles. Their binding to DNA requires homo- or heterodimerization via alpha-helical domains, which generally do not contain obvious binding sites for small molecules. We have identified two small molecules, dubbed Mycro1 and Mycro2, which inhibit the protein-protein interactions between the bHLHZip proteins c-Myc and Max. Mycros are the first inhibitors of c-Myc/Max dimerization, which have been demonstrated to inhibit DNA binding of c-Myc with preference over other dimeric transcription factors in vitro. Mycros inhibit c-Myc-dependent proliferation, gene transcription, and oncogenic transformation in the low micromolar concentration range. Our data support the idea that dimeric transcription factors can be druggable even in the absence of obvious small-molecule binding pockets.
bZip和bHLHZip蛋白家族成员构成了真核转录因子的很大一部分,并且需要结合DNA才能发挥其大部分基本生物学作用。它们与DNA的结合需要通过α-螺旋结构域进行同源或异源二聚化,而α-螺旋结构域通常不包含明显的小分子结合位点。我们鉴定出了两种小分子,分别称为Mycro1和Mycro2,它们可抑制bHLHZip蛋白c-Myc和Max之间的蛋白质-蛋白质相互作用。Mycro是c-Myc/Max二聚化的首批抑制剂,已证明它们在体外优先于其他二聚体转录因子抑制c-Myc与DNA的结合。Mycro在低微摩尔浓度范围内可抑制c-Myc依赖性增殖、基因转录和致癌转化。我们的数据支持这样一种观点,即即使在没有明显小分子结合口袋的情况下,二聚体转录因子也可以成为可药物作用的靶点。